All doses of Novo Nordisk’s blockbuster diabetes and obesity drugs were listed as available on the FDA shortage list as of ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at ... FDA and has called for ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

The largest air cargo operators play an essential role in this ecosystem, employing vast fleets of dedicated freighters and ...

Hospital and pharmaceutical groups have said previously that tariffs could deepen financial stress on health systems.

ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 17. Joseph ...

Add articles to your saved list and come back to them any time ... Richard Lee, chief executive of Liber Pharmaceuticals, ...